{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"4"}]}],"title":"partial response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"13"}]}],"title":"stable disease"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"6"}]}],"title":"progressive disease"}],"denoms":[{"counts":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"23"}],"units":"Participants"}],"description":"Radiologic assessments of measurable disease will be performed using radiographic imaging. RECIST 1.1 and immune response criteria will be used to assess response to therapy. Responses will be summarized as frequencies and percentages.","groups":[{"description":"Head and Neck Squamous Cell RECIST 1.1","id":"OG000","title":"Head and Neck Squamous Cell"},{"description":"RECIST 1.1 response rate salivary gland","id":"OG001","title":"Salivary Gland Carcinoma"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"6 patients were not evaluated as they did not have at least 1 set of follow up scans while on study, (N=2 salivary patients, N=4 SCC patients)","reportingStatus":"POSTED","timeFrame":"Up to 2 years","title":"Objective Response Rate","type":"SECONDARY","unitOfMeasure":"Participants"}